This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study (Bo-CRISP)

This study has been completed.
Information provided by (Responsible Party):
Saskia Meves, Ruhr University of Bochum Identifier:
First received: April 26, 2013
Last updated: NA
Last verified: April 2013
History: No changes posted
The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.

Ischemic Stroke

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.

Resource links provided by NLM:

Further study details as provided by Saskia Meves, Ruhr University of Bochum:

Primary Outcome Measures:
  • Result of platelet function test [ Time Frame: one day ]
    Aggregometry result of antiplatelet therapy

Enrollment: 159
Study Start Date: July 2010
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
acute ischemic stroke
Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with an acute ischemic stroke admitted to our stroke unit and treated with clopidogrel

Inclusion Criteria:

  • acute ischemic stroke
  • admittance to stroke unit
  • clopidogrel medication

Exclusion Criteria:

  • no consent
  • prior bleeding disorders
  • severe liver disorders
  • current gastrointestinal disorders
  • congestive heart failure
  • life-threatening malignancies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01843361

Department of Neurology, Ruhr University Bochum
Bochum, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Principal Investigator: Saskia H Meves, MD Ruhr University Bochum, Department of Neurology
  More Information

Responsible Party: Saskia Meves, MD, Ruhr University of Bochum Identifier: NCT01843361     History of Changes
Other Study ID Numbers: Meves-clopi-01
Study First Received: April 26, 2013
Last Updated: April 26, 2013

Keywords provided by Saskia Meves, Ruhr University of Bochum:
Antiplatelet therapy
Platelet function tests

Additional relevant MeSH terms:
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Fibrinolytic Agents
Fibrin Modulating Agents
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on September 19, 2017